SCHEMBL1099672

SCHEMBL1099672

Cc1c(N(Cc2ccc(F)c(C(F)(F)F)c2)S(=O)(=O)c2cccnc2C=S)sc2ccccc12

nearest known ligand 0.62

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 17/20 0.62
RPS6KB1 P23443 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.32
CXCR3 P49682 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1100238 0.89 TRPM8 (0.64) TRPM8RPS6KB1CXCR3
SCHEMBL1098704 0.88 TRPM8 (0.63) TRPM8RPS6KB1
SCHEMBL1099096 0.87 TRPM8 (0.62) TRPM8RPS6KB1
SCHEMBL1100089 0.86 TRPM8 (0.60) TRPM8
SCHEMBL1100067 0.84 TRPM8 (0.62) TRPM8RPS6KB1
SCHEMBL1099065 0.82 TRPM8 (0.71) TRPM8
SCHEMBL1099527 0.81 TRPM8 (0.67) TRPM8
SCHEMBL1099135 0.81 TRPM8 (0.71) TRPM8
SCHEMBL1099199 0.81 TRPM8 (0.62) TRPM8RPS6KB1
SCHEMBL1098897 0.80 TRPM8 (0.64) TRPM8PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-8809327-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-08-19 US disclosed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 EP disclosed
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS BRANUM SHAWN T (US) 2012-07-26 US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885RPS6KB1 549/4885PTGDR2 312/4885
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885RPS6KB1 549/4885PTGDR2 312/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885RPS6KB1 549/4885PTGDR2 312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.